Welcome to our dedicated page for HilleVax news (Ticker: HLVX), a resource for investors and traders seeking the latest updates and insights on HilleVax stock.
HilleVax Inc. news centered on its clinical-stage vaccine business, including development updates for HIL-214 and HIL-216, virus-like particle vaccine candidates for norovirus-associated acute gastroenteritis. Company updates also covered clinical data from the NEST-IN1 study, the discontinuation of HIL-214 development in infants, and evaluation of adult norovirus vaccine opportunities.
Recurring HLVX news also included operating and financial results, research and development spending, cash and marketable securities, workforce and expense actions, material agreements, shareholder matters, capital-structure disclosures, governance matters, risk factors, and corporate-status developments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.